This observation underscores the critical impact of severe comorbidities, particularly renal impairment, on survival outcomes in RA patients on anti-TNF therapy, indicating a vulnerability not fully mitigated by anti-TNF treatment [34]. The gene discussed is TNF; the disease is rheumatoid arthritis.